How modeling and simulation can bring new immuno-oncology treatments to patients
Immuno-oncology, which harnesses the patient's own immune system to fight cancer, is one of the…
Certara2016 年 2 月 16 日
Population PK & Dosing Implications for Cobimetinib in Cancer Patients
A population pharmacokinetic model was developed for cobimetinib in cancer patients. Covariates had minimal impact…
Certara2015 年 11 月 1 日
Modeling & Simulation Relating Survival to Tumor Growth Inhibition in Patients
The published OS model and resultant simulations can be leveraged to support Phase II design…
Certara2015 年 9 月 1 日
Population Pharmacokinetic Modeling of Motesanib and Its Active Metabolite, M4, in Cancer Patients
Motesanib is a small molecule and potent multikinase inhibitor with antiangiogenic and antitumor activity. Population…
Certara2015 年 7 月 23 日
Population Pharmacokinetic Analysis of Thrombomodulin Alfa to Support Dosing Rationale in Patients with Renal Impairment
Thrombomodulin alfa is a soluble recombinant human thrombomodulin that was reported to enhance the reversal…
Certara2015 年 5 月 1 日
Onartuzumab with or without Bevacizumab in Combination with Weekly Paclitaxel Does Not Prolong QTc or Adversely Affect Other ECG Parameters in Patients with Locally Recurrent or Metastatic Triple-negative Breast Cancer
The purpose of this study was to examine the potential effect of onartuzumab, when administered…
Certara2014 年 12 月 17 日
Assessment of Tumor Growth Inhibition Metrics to Predict Overall Survival
Modeling and simulation is proposed to support drug development phase transitions in oncology. Longitudinal tumor-size…
Certara2014 年 8 月 1 日
Model-based Meta-analysis for Quantifying Paclitaxel Dose Response in Cancer Patients
Model-based meta-analysis of dose response is a sophisticated method to guide dose and regimen selection.…
Certara2014 年 5 月 21 日
